NCT04440488View on ClinicalTrials.gov

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 8, 2021

Primary Completion Date

September 12, 2025

Study Completion Date

September 12, 2025

Conditions

Chronic Obstructive Pulmonary DiseaseAlpha1-antitrypsin Deficiency

Interventions

BIOLOGICAL

ARALAST NP

Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY